Search clinical trials for: Weekly paclitaxel

Total 5239 results

Renmin Hospital of Wuhan University

Recruiting

A Study of Chemoradiation in Combination With Tislelizumab as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Centre Georges Francois Leclerc

Recruiting

Randomized Study Versus Placebo for the Prevention of Neurotoxicity Induced by Weekly PACLITAXEL (NEUROTAX)

Breast Cancer

France
M.D. Anderson Cancer Center
Jazz Pharmaceuticals

Recruiting

Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

Ovarian Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
ImmunoRestoration

Recruiting

Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

HER2-positive Breast Cancer

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer

Recurrent Platinum-resistant Ovarian Cancer

China
Chipscreen Biosciences, Ltd.

Recruiting

Chiauranib Plus Weekly Paclitaxel in Patients With Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer (CHIPRO)

Ovarian Cancer | Relapsed or Refractory | Chiauranib | Paclitaxel

China
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Recruiting

First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

Head Neck Cancer | Oropharynx Squamous Cell Carcinoma | Oral Cavity Squamous Cell Carcinoma | Metastatic Squamous Cell Carcinoma | Hypopharynx Squamous Cell Carcinoma | Larynx Squamous Cell Carcinoma

United States
Immunicom Inc

Recruiting

Immunopheresis Alone or in Combination With Paclitaxel or Atezolizumab in Non-small Cell Lung Cancer (NSCLC).

Non Small Cell Lung Cancer

Turkey
Fondazione Policlinico Universitario Agostino Gemelli...
GlaxoSmithKline

Recruiting

Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment (NItCHE-MITO33)

Ovarian Cancer

Italy
National Cancer Center, Korea
Korean Cancer Study Group

Recruiting

EGFR-targeted Therapy for Gastric Cancer

Adenocarcinoma of the Stomach

Korea, Republic of
Ira Winer

Recruiting

ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Malignant Ovarian Epithelial Tumor | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian... and other conditions

United States
1Globe Health Institute LLC

Recruiting

A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer

Metastatic Pancreatic Cancer

Spain, China, France
NSABP Foundation Inc
Genentech, Inc.; Celcuity, LLC

Recruiting

Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling (FB-12)

HER2-negative Breast Cancer

United States
Chang Gung Memorial Hospital
Asian Gynecologic Oncology Group; Taiwanese Gynecologic Oncology Group

Recruiting

Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and IIA2 Cervical Cancer Followed by Radical Hysterectomy

Cervical Cancer

Taiwan
Lucia Del Mastro,MD

Completed

Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer

HER-2 Positive Breast Cancer

Italy
NovoCure Ltd.

Completed

Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)

Ovarian Cancer

United States, Israel, Belgium, Netherlands, Hungary, Germany, Poland, Canada, Austria, Czechia, Italy, Spain, Switzerland
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Gateway for Cancer Research

Active, not recruiting

TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Primary Peritoneal Cancer | Fallopian Tube | Epithelial Ovarian

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in First-line NSCLC (JAVELIN Lung 100)

First Line Non-Small Cell Lung Cancer

Spain, United States, Hungary, Israel, China, Korea, Republic of, Taiwan, Czechia, Russian Federation, Australia, Brazil, Lebanon, Serbia, Thailand, Canada, Slovakia, Ukraine, Bulgaria, Italy, Netherlands, New Zealand, Poland, Belgium, Turk... and more
Queen Mary University of London
Merck Sharp & Dohme LLC; European Institute of Oncology

Withdrawn

Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast Cancer (PELICAN)

Breast Cancer
University of Illinois at Chicago

Active, not recruiting

Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer

Triple Negative Breast Cancer

United States
Tata Memorial Hospital

Active, not recruiting

A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer

India
QuantumLeap Healthcare Collaborative
Byondis B.V.

Withdrawn

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Ovarian Cancer | Metastatic Cancer | Metastatic Breast Cancer | Bladder Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Gastroesophageal Adenocarcinoma | Ovarian Carcinoma | HER2-positive Gastric Cancer | Metastatic Gastrointestinal Carcinoid Tumor | HER2-positive Metastatic Breast... and other conditions

United States
Sumitomo Pharma America, Inc.

Terminated

A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer (CanStem43L)

Carcinoma, Non-Small-Cell Lung

United States
Sumitomo Pharma America, Inc.

Completed

A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer (BRIGHTER)

Gastric Cancer | Gastroesophageal Junction Cancer

United States, Hungary, Spain, China, Brazil, France, Australia, Czechia, Germany, Israel, Canada, United Kingdom, Japan, Belgium, Romania, Italy, Poland, Lithuania, Korea, Republic of, Bulgaria, Estonia, Russian Federation
Abramson Cancer Center at Penn Medicine

Completed

A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer

Advanced Breast Cancer

United States
Advenchen Laboratories, LLC

Active, not recruiting

Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) (AL3818)

Fallopian Tube Carcinoma | Cervical Carcinoma | Endometrial Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma

Korea, Republic of, Spain, United States, United Kingdom, China, Italy
University of Wisconsin, Madison

Completed

Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response

Breast Neoplasm Female

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Terminated

Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca

Breast Cancer

United States
RenJi Hospital

Active, not recruiting

Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients (SHPD002)

Inflammatory Breast Cancer | Invasive Ductal Breast Cancer | Tubular Breast Cancer | Mucinous Breast Cancer

China
Belgian Gynaecological Oncology Group
Grupo Español de Investigación en Cáncer de Ovario; Mario Negri Gynecologic... and other collaborators

Active, not recruiting

ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix Cancer

Uterine Cervical Neoplasms

Spain, Belgium, Germany, Italy
Cairo University
Misr International University

Completed

Comparison of Weekly Versus Every Three Weeks of Carboplatin Plus Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer

Advanced Epithelial Ovarian Cancer

Egypt
Memorial Sloan Kettering Cancer Center

Completed

Acupuncture to Reduce Chemotherapy-induced Peripheral Neuropathy Severity During Neoadjuvant or Adjuvant Weekly Paclitaxel Chemotherapy in Breast Cancer Patients

Breast Cancer | Peripheral Neuropathy

United States
SCRI Development Innovations, LLC
Bristol-Myers Squibb

Completed

Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma

Neuroendocrine Carcinoma
Cancer Trials Ireland

Completed

A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer (TH V THL)

Metastatic Breast Cancer

Spain, Ireland, Israel, Finland, Portugal, France, Germany, Norway
National Cancer Institute, Naples

Active, not recruiting

Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer (MITO-7)

Ovarian Cancer

Italy
Immutep S.A.S.

Withdrawn

A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel (AIPAC-002)

Metastatic Breast Cancer
Spanish Breast Cancer Research Group
Bristol-Myers Squibb

Completed

FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients

Breast Cancer

Spain
Spanish Breast Cancer Research Group
Bristol-Myers Squibb; Pfizer; Hoffmann-La Roche

Completed

Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer

Breast Cancer

Spain
University College, London
Merck Sharp & Dohme LLC

Active, not recruiting

Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer (PROMPT)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United Kingdom
AstraZeneca

Completed

Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients (BEECH)

Advanced or Metastatic Breast Cancer | ER+ve Advanced or Metastatic Breast Cancer

Canada, France, Korea, Republic of, Czechia, Peru, United Kingdom, Spain, Japan, Mexico, Singapore, Bulgaria
Yale University

Completed

Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer

Breast Neoplasms

United States
Floor Backes
Eisai Inc.

Completed

Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer

Fallopian Tube Carcinoma | Recurrent Endometrial Cancer | Primary Peritoneal Carcinoma | Recurrent Ovarian Cancer

United States
BioNumerik Pharmaceuticals, Inc.
Lantern Pharma Inc. became Sponsor of Tavocept (BNP7787) IND 051014 as of...

Completed

Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel

Breast Neoplasms | Breast Diseases | Metastases, Neoplasm
Case Comprehensive Cancer Center

Terminated

Weight-based Dosing for Dense Weekly Paclitaxel and Carboplatin in Overweight Patients w/ Body Surface Area (BSA) > 2.0

Gynecologic Malignancies

United States
Yonsei University

Active, not recruiting

Two-Part, Phase Ib/II, Open Label, Single-Arm, Multi-center Study to Evaluate the Safety and Efficacy of Varlitinib in Combination With Weekly Paclitaxel in EGFR/HER2 Co-expressing Advanced or Metastatic Gastric Cancer Patients

Gastric Cancer

Korea, Republic of
Bristol-Myers Squibb

Completed

Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer

Head and Neck Cancer

Japan
NSABP Foundation Inc
Eisai Inc.

Completed

Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer

Breast Cancer | HER2-negative Breast Cancer

United States, Canada
Dompé Farmaceutici S.p.A
PRA Health Sciences

Completed

Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)

Metastatic Breast Cancer

United States
Fondazione Policlinico Universitario Agostino Gemelli...

Completed

Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients (MITO23)

Ovarian Neoplasms

Italy
ARCAGY/ GINECO GROUP
Roche Pharma AG

Completed

Efficacy and Safety of Bevacizumab (Avastin®) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin®) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours (ALIENOR) (ALIENOR)

Ovarian Sex-cord Stromal Tumor

France

Search clinical trials for: Weekly paclitaxel

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations